glp-1 receptor agonist with dpp-4 inhibitor combination not recommended Comparison of agonists and inhibitors Lesson: A Clinical Overview of

10.1007/s00125-001-0719-z 4 AlhadeffA

works closely with patients to evaluate medical history, lifestyle factors, and treatment goals before recommending a GLP-1 therapy

Information or Data Analysis 1.3.3

However, there is a growing interest in natural compounds that can enhance GLP-1 activity, offering more accessible and potentially safer alternatives

ALT is 8090 % sensitive 7080 % specific in identifying Pediatric MASLD with AUROC of 0.80 in response to treatment [51,52].Routine US is discouraged as a screening test due to its inadequate sensitivity and specificity, especially when liver fat is less than 30 % or in cases where BMI exceeds 40 kg/m 2 [53]

New York, NY: McGraw-Hill